Comparative study of schizophrenic patients relapsed on and off medication. 1987

G Bartkó, and E Mayláth, and I Herczeg
National Institute for Nervous and Mental Diseases, Budapest, Hungary.

The frequency of stressful life events, the characteristic psychopathological features, and the course of relapse were studied in 22 schizophrenic patients who relapsed while on maintenance neuroleptic medication and 27 noncompliant patients off treatment. The patients who relapsed while on neuroleptics experienced more independent life events, mainly losses and family conflicts, in the months preceding admission. Patients who relapsed while not on drugs were characterized by a more severe psychopathological picture dominated by positive symptoms at admission. Schizophrenic patients who relapsed on medication showed greater improvement and required shorter hospitalization.

UI MeSH Term Description Entries
D008016 Life Change Events Those occurrences, including social, psychological, and environmental, which require an adjustment or effect a change in an individual's pattern of living. Life Course,Life Crises,Life Crisis,Life Experiences,Course, Life,Crisis, Life,Event, Life Change,Experience, Life,Life Change Event,Life Courses,Life Experience
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002746 Chlorpromazine The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. Aminazine,Chlorazine,Chlordelazine,Chlorpromazine Hydrochloride,Contomin,Fenactil,Largactil,Propaphenin,Thorazine,Hydrochloride, Chlorpromazine
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

G Bartkó, and E Mayláth, and I Herczeg
August 1992, Archives of general psychiatry,
G Bartkó, and E Mayláth, and I Herczeg
January 1971, Current therapeutic research, clinical and experimental,
G Bartkó, and E Mayláth, and I Herczeg
January 1989, Psychopathology,
G Bartkó, and E Mayláth, and I Herczeg
August 1972, Diseases of the nervous system,
G Bartkó, and E Mayláth, and I Herczeg
December 1975, The American journal of psychiatry,
G Bartkó, and E Mayláth, and I Herczeg
January 2001, Journal of addictive diseases,
G Bartkó, and E Mayláth, and I Herczeg
December 1980, MMW, Munchener medizinische Wochenschrift,
G Bartkó, and E Mayláth, and I Herczeg
October 1984, Indian journal of psychiatry,
G Bartkó, and E Mayláth, and I Herczeg
November 1981, The Journal of nervous and mental disease,
Copied contents to your clipboard!